NVAXNovavax, Inc.

$2B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$36M+958.6% YoY

Gross Profit

$36M100.0% margin

Operating Income

-$17M-47.9% margin

Net Income

-$18M-49.3% margin

EPS (Diluted)

$-0.30

QoQ Revenue Growth

+952.4%

Cash Flow

Operating Cash Flow

$116M

Free Cash Flow

$112M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$932M

Total Liabilities

$748M

Stockholders' Equity

$185M

Cash & Equivalents

$424M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$36M	$3M	+958.6%
Gross Profit	$36M	$3M	+958.6%
Operating Income	-$17M	-$37M	+53.6%
Net Income	-$18M	-$40M	+55.8%

Revenue Segments

Grant

$36M100%

NVAX Q2 2020 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena